95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1555114
This article is part of the Research Topic Renewed Insight into Cancer Mechanism and Therapy View all 24 articles
Best evidence summary for preventing and managing epidermal growth factor receptor inhibitors induced paronychia in cancer patients
Provisionally accepted- 1 Ningbo Second Hospital, Ningbo, Zhejiang Province, China
- 2 Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
Objective To evaluate and summarize the best evidence for preventing and managing epidermal growth factor receptor inhibitors induced paronychia in cancer patients. It aims to provide a reference for medical staff. Methods We systematically searched for evidence on paronychia symptoms in 14 databases such as Cnki、Wanfang, 7 guide websites such as GIN and NZGG, and 8 professional websites such as UICC and ACS from database establishment to August 2024. Two researchers evaluated the quality of the literature and extracted the data. Results A total of 20 articles were included in this study, including 5 clinical decisions 、 5 guidelines 、 3 evidence summaries 、3 recommended practices, and 4 experts consensuses. Finally, 12 pieces of evidence were summarized from 4 aspects, including risk factor assessment, professional healthcare training, preventive measures, and therapeutic measures.Our research summarizes the best evidence for preventing and managing epidermal growth factor receptor inhibitors induced by paronychia in cancer patients.In the actual clinical application, it is necessary to fully consider the clinical situation, combine the judgment of professionals and patients' wishes, follow the principle of individualization, analyze the obstacles and facilitating factors of the application of evidence, and apply the evidence to the clinical practice prudently.
Keywords: Cancer, target therapy, Epidermal growth factor receptor inhibitors, Paronychia, evidence summary
Received: 03 Jan 2025; Accepted: 24 Feb 2025.
Copyright: © 2025 Li, Qiu, Zhang and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiuyue Qiu, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.